2022
DOI: 10.1007/s00223-022-00972-2
|View full text |Cite
|
Sign up to set email alerts
|

Osteoporosis and Bone Health in Transgender Individuals

Abstract: This review discusses the changes in bone mass, structure, and metabolism that occur upon gender-affirming hormonal treatment (GAHT) in transgender adults and adolescents, as well as their clinical relevance. In general, available evidence shows that GAHT in transgender adults is not associated with major bone loss. In transgender adolescents, pubertal suppression with gonadotropin-releasing hormone agonist monotherapy impairs bone development, but at least partial recovery is observed after GAHT initiation. N… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(14 citation statements)
references
References 51 publications
0
13
0
1
Order By: Relevance
“…Zn is an important factor in bone health [ 197 ]. Although GAHT in adults has not shown major bone impacts, such treatments have recorded impaired bone development in adolescents [ 198 ]. However, whether such impairments occur through GAHT impacts on Zn uptake in transgender women is not yet known.…”
Section: Resultsmentioning
confidence: 99%
“…Zn is an important factor in bone health [ 197 ]. Although GAHT in adults has not shown major bone impacts, such treatments have recorded impaired bone development in adolescents [ 198 ]. However, whether such impairments occur through GAHT impacts on Zn uptake in transgender women is not yet known.…”
Section: Resultsmentioning
confidence: 99%
“…A prospective cohort study assessed BMD at set intervals after initiation of pubertal blockade found that z-scores decreased for the first two years after initiation of pubertal blockade [30 ▪ ]. Despite these risks, TGD adults on GAHT have parity in fracture risk with cisgender controls of their affirmed gender [33]. Additionally, GnRH agonists temporarily impair spermatogenesis and oocyte maturation while in use [13].…”
Section: Management Of Gender Dysphoriamentioning
confidence: 99%
“…Gender affirming treatment can impact BMD. In adolescents, GnRH agonists may decrease BMD and may compound the bone density loss induced by restriction [ 74 , 75 ]. Adolescence is a vulnerable time for BMD development as it represents the time of peak bone accrual.…”
Section: Additional Medical Considerationsmentioning
confidence: 99%